Viking initiates study to evaluate dual GLP-1/GIP receptor agonist VK2735Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...
AMGEN presents ‘encouraging’ AMG 133 weight loss resultsAmgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
STEP 8: Greater weight loss for once-weekly semaglutide vs daily liraglutideOnce-weekly subcutaneous semaglutide (2.4mg) is more effective on weight loss in conjunction with counselling and physical activity vs...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes13 hours ago